Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 26, 2012

Primary Completion Date

December 27, 2023

Study Completion Date

December 27, 2023

Conditions

GliomaNeuroectodermal Tumors, PrimitiveWilms TumorRhabdomyosarcomaSarcoma, EwingOsteosarcomaRetinoblastoma

Interventions

DRUG

Metronomic Cyclophosphamide

DRUG

Thalidomide

Trial Locations (1)

Washington University School of Medicine, St Louis

All Listed Sponsors

lead

Washington University School of Medicine

OTHER

NCT01661400 - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors | Biotech Hunter | Biotech Hunter